Survodutide (BI 456906) is an investigational unimolecular dual agonist developed by Boehringer Ingelheim (licensed from Zealand Pharma) that activates both the glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR). Based on a modified glucagon backbone with C18 fatty acid acylation supporting once-weekly dosing, it is currently being evaluated in Phase 3 clinical trials (SYNCHRONIZE program) and represents an area of active incretin receptor research. This research-grade lyophilized powder is synthesized under strict quality controls and provided with full analytical documentation. For Research Use Only. Not for human use.
Key Scientific Attributes
- High-purity Survodutide (≥98% by HPLC/MS, acetate salt form)
- Verified 29-amino-acid glucagon-based sequence with C18 diacid lipidation
- Lyophilized formulation for maximum long-term stability
- Full Certificate of Analysis (COA) with HPLC, MS, receptor-binding assays (GLP-1R/GCGR EC50), and endotoxin testing
- Manufactured in GMP-aligned, ISO-compliant facilities
- Suitable for dual-agonist receptor signaling studies and related in vitro pathway research
Research Context (Based on published clinical/preclinical literature; not therapeutic claims.)
- Dual GLP-1R/GCGR activation profile as described in peer-reviewed pharmacological studies (pubmed.ncbi.nlm.nih.gov)
- Pharmacological profiling and biomarker characterization published in the scientific literature
- Subject of ongoing Phase 3 investigation (SYNCHRONIZE-2) in peer-reviewed research settings (pubmed.ncbi.nlm.nih.gov)
- Evaluated across metabolic, hepatic, and receptor signaling research models in published literature
Why Researchers Choose Nationwide Peptides Survodutide
- Exact clinical-sequence match to BI 456906 with verified dual-receptor potency
- Transparent analytical data (HPLC >98%, MS confirmation of lipidation)
- Trusted by pharmacology and molecular biology laboratories
- Competitive research pricing with bulk options
For Research Use Only. Not for human use.
